Immune Therapeutics Inc logo

IMUN - Immune Therapeutics Inc Share Price

$0.015 -0.0  -9.4%

Last Trade - 16/04/21

Micro Cap
Market Cap £4.87k
Enterprise Value £2.07m
Revenue £n/a
Position in Universe 6801st / 6850
Unlock IMUN Revenue
Relative Strength (%)
1m -34.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -70.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.016 0.003 0.000 0.11 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ImmuneTherapeutics Inc revenues was not reported. Net incometotaled $2.5M vs. loss of $2.5M. Net income reflects Gainon settlement of debt increase from $0K to $3.3M (income),Selling/General/Admin. Expense decrease of 62% to $516K(expense), Gain/(Loss) on valuation derivative increasefrom $585K (expense) to $197K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IMUN Revenue Unlock IMUN Revenue

Net Income

IMUN Net Income Unlock IMUN Revenue

Normalised EPS

IMUN Normalised EPS Unlock IMUN Revenue

PE Ratio Range

IMUN PE Ratio Range Unlock IMUN Revenue

Dividend Yield Range

IMUN Dividend Yield Range Unlock IMUN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IMUN EPS Forecasts Unlock IMUN Revenue
Profile Summary

Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated December 2, 1993
Public Since July 16, 2001
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Pink Sheets on Nasdaq
Shares in Issue 464,470
Free Float (0.0%)
Eligible for
× ISAs
IMUN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IMUN
Upcoming Events for IMUN
Frequently Asked Questions for Immune Therapeutics Inc
What is the Immune Therapeutics Inc share price?

As of 16/04/21, shares in Immune Therapeutics Inc are trading at $0.015, giving the company a market capitalisation of £4.87k. This share price information is delayed by 15 minutes.

How has the Immune Therapeutics Inc share price performed this year?

Shares in Immune Therapeutics Inc are currently trading at $0.015 and the price has moved by -2.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Immune Therapeutics Inc price has moved by -34.51% over the past year.

What are the analyst and broker recommendations for Immune Therapeutics Inc?

There are no analysts currently covering Immune Therapeutics Inc.

When will Immune Therapeutics Inc next release its financial results?

Immune Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Immune Therapeutics Inc dividend yield?

Immune Therapeutics Inc does not currently pay a dividend.

Does Immune Therapeutics Inc pay a dividend?

Immune Therapeutics Inc does not currently pay a dividend.

When does Immune Therapeutics Inc next pay dividends?

Immune Therapeutics Inc does not currently pay a dividend.

How do I buy Immune Therapeutics Inc shares?

To buy shares in Immune Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Immune Therapeutics Inc?

Shares in Immune Therapeutics Inc are currently trading at $0.015, giving the company a market capitalisation of £4.87k.

Where are Immune Therapeutics Inc shares listed? Where are Immune Therapeutics Inc shares listed?

Here are the trading details for Immune Therapeutics Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: IMUN
What kind of share is Immune Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Immune Therapeutics Inc is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Immune Therapeutics Inc share price forecast 2021?

We were not able to load any forecast data for Immune Therapeutics Inc.

How can I tell whether the Immune Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immune Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -9.63%. At the current price of $0.015, shares in Immune Therapeutics Inc are trading at -25.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Immune Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Immune Therapeutics Inc.

Who are the key directors of Immune Therapeutics Inc?

Immune Therapeutics Inc's management team is headed by:

Nicholas Plotnikoff - NEC
Christopher Pearce - DRC
Paul Akin - IND
Peter Aronstam - CFO
Fengping Shan - OTH
Joseph Fortunak - VRD
Rudy Williams - COO
Kevin Phelps - PRE
Who are the major shareholders of Immune Therapeutics Inc?

Here are the top five shareholders of Immune Therapeutics Inc based on the size of their shareholding:

Magnolia Capital Advisors LLC Investment Advisor
Percentage owned: 4.77% (23.0k shares)
Ahmetaj (Erjon) Individual Investor
Percentage owned: 4.64% (22.3k shares)
MAI Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 2.59% (12.5k shares)
Griffin (Noreen) Individual Investor
Percentage owned: 0.79% (3.82k shares)
Teraskiewic (Edward) Individual Investor
Percentage owned: 0.74% (3.55k shares)
Similar to IMUN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.